2.508 The HMG-CoA reductase inhibitor lovastatin reduces incidence of L-Dopa-induced abnormal involuntary movements in experimental Parkinson's disease

2007 ◽  
Vol 13 ◽  
pp. S144
Author(s):  
S. Schuster ◽  
A. Nadjar ◽  
J.T. Guo ◽  
Q. Li ◽  
C. Ittrich ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Reductase Inhibitor ◽  
Abnormal Involuntary Movements ◽  
Hmg Coa Reductase ◽  
Involuntary Movements ◽  
Hmg Coa Reductase Inhibitor ◽  
Coa Reductase

Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells

2004 ◽  
Author(s):  
Takemi Otsuki ◽  
Haruko Sakaguchi ◽  
Tamayo Hatayama ◽  
Tomohiro Fujii ◽  
Takayuki Tsujioka ◽  
...  
Keyword(s):  
Reductase Inhibitor ◽  
Hmg Coa Reductase ◽  
Myeloma Cells ◽  
Hmg Coa Reductase Inhibitor ◽  
Coa Reductase ◽  
Human Myeloma Cells

Treatment of hypercholesterolemia with the HMG CoA reductase inhibitor, simvastatin

1989 ◽  
Vol 3 (2) ◽  
pp. 219-227 ◽  
Author(s):  
GMB Berger ◽  
AD Marais ◽  
HC Seftel ◽  
SG Baker ◽  
D Mendelsohn ◽  
...  
Keyword(s):  
Reductase Inhibitor ◽  
Hmg Coa Reductase ◽  
Hmg Coa Reductase Inhibitor ◽  
Coa Reductase

Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor

1988 ◽  
Vol 66 (10) ◽  
pp. 462-463 ◽  
Author(s):  
J. Thiery ◽  
V. W. Armstrong ◽  
J. Schleef ◽  
C. Creutzfeldt ◽  
W. Creutzfeldt ◽  
...  
Keyword(s):  
Reductase Inhibitor ◽  
Serum Lipoprotein ◽  
Hmg Coa Reductase ◽  
Hmg Coa Reductase Inhibitor ◽  
Coa Reductase
Sign in / Sign up

Export Citation Format

Share Document